{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:39:38Z","timestamp":1794627578676,"version":"4.9.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":447,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"DOI":"10.1513\/annalsats.202407-694ed","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:00:04Z","timestamp":1730455204000},"page":"1483-1484","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":4,"title":["Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S.","family":"Quon","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, and"},{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2026012203180510500_bib1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"2026012203180510500_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2018.11.010","article-title":"Beyond the expected: identifying broad research priorities of researchers and the cystic fibrosis community","volume":"18","author":"Hollin","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012203180510500_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1513\/AnnalsATS.202404-366OC","article-title":"Impact of discontinuing both hypertonic saline and dornase alfa after elexacaftor-tezacaftor-ivacaftor in cystic fibrosis","volume":"21","author":"Mayer-Hamblett","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203180510500_bib8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2023.05.001","article-title":"Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"23","author":"Manika","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib10","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ppul.27018","article-title":"Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"59","author":"De Vuyst","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026012203180510500_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1513\/AnnalsATS.202308-735RL","article-title":"Assessing safety of discontinuing hypertonic saline in those with lower forced expiratory volume in 1 second after elexacaftor\/tezacaftor\/ivacaftor","volume":"21","author":"Nichols","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203180510500_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: the SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203180510500_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2024.02.003","article-title":"The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor\/tezacaftor\/ivacaftor treated people with cystic fibrosis: the SIMPLIFY-MCC Study","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026012203180510500_bib14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O\u2019Donnell","year":"1998","journal-title":"Chest"},{"key":"2026012203180510500_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1483\/66014002\/annalsats_21_11_1483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1483\/66014002\/annalsats_21_11_1483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:19:12Z","timestamp":1769069952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/11\/1483\/8380703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202407-694ed","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2024-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}